REVB vs. BCEL, BPTS, PHAS, MBIO, ARDS, GOVX, ARAV, SXTP, PHIO, and EVOK
Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Atreca (BCEL), Biophytis (BPTS), PhaseBio Pharmaceuticals (PHAS), Mustang Bio (MBIO), Aridis Pharmaceuticals (ARDS), GeoVax Labs (GOVX), Aravive (ARAV), 60 Degrees Pharmaceuticals (SXTP), Phio Pharmaceuticals (PHIO), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical preparations" industry.
Atreca (NASDAQ:BCEL) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.
37.5% of Atreca shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 11.3% of Atreca shares are owned by insiders. Comparatively, 0.2% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Atreca had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 3 mentions for Atreca and 1 mentions for Revelation Biosciences. Atreca's average media sentiment score of 1.00 beat Revelation Biosciences' score of 0.46 indicating that Revelation Biosciences is being referred to more favorably in the news media.
Atreca has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
Atreca presently has a consensus price target of $4.00, suggesting a potential upside of 4,900.00%. Given Revelation Biosciences' higher probable upside, research analysts clearly believe Atreca is more favorable than Revelation Biosciences.
Atreca's return on equity of -84.25% beat Revelation Biosciences' return on equity.
Atreca is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Atreca received 65 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote.
Summary
Atreca beats Revelation Biosciences on 7 of the 13 factors compared between the two stocks.
Get Revelation Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revelation Biosciences Competitors List
Related Companies and Tools
